m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05546
 [1]
m6A modification DLGAP1-AS1 DLGAP1-AS1 WTAP Methylation : m6A sites Direct Enhancement Non-coding RNA DLGAP1-AS1 miR-299-3p  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Wilms tumor 1-associating protein (WTAP) WRITER
 Regulator Info 
m6A Target DLGAP1 antisense RNA 1 (DLGAP1-AS1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator DLGAP1 antisense RNA 1 (DLGAP1-AS1) LncRNA View Details
Regulated Target hsa-miR-299-3p View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary LncRNA DLGAP1-AS1 promotes BC ADR-resistance through WTAP/DLGAP1 antisense RNA 1 (DLGAP1-AS1)/hsa-miR-299-3p feedback loop in breast cancer.
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Responsed Drug ADR
 Drug Info 
Cell Process Cell proliferation
Cell growth
In-vitro Model
 MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
BT-549 Invasive breast carcinoma Homo sapiens CVCL_1092
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
NCI-ADR-RES
 N.A. Homo sapiens CVCL_1452
MCF-10A Normal Homo sapiens CVCL_0598
In-vivo Model For xenograft tumor model, 5-week-old male BALB/c nude mice (n = 10) were gained from Beijing Laboratory Animal Center (Beijing, China). BC cells (MCF-7/ADR, 1 × 107 cells/0.2 mL PBS:Matrigel = 1:3, v/v) were transfected with NC or sh-DLGAP1-AS1 and then subcutaneously implanted into the flank of mice. Every 3 days, the length and width were recorded and calculated for the volume: V = (width2× length × 0.52). At the indicated time, nude mice were sacrificed, and the parameters of tumor weight were detected.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C60: Breast cancer 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Entrectinib Approved [2]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Everolimus Approved [3]
External Link
CID: 6442177
TTD: D09ZSC
DrugBank: DB01590
References
Ref 1 N(6)-methyladenosine (m(6)A)-mediated lncRNA DLGAP1-AS1enhances breast canceradriamycin resistance through miR-299-3p/WTAP feedback loop. Bioengineered. 2021 Dec;12(2):10935-10944. doi: 10.1080/21655979.2021.2000198.
Ref 2 Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015